UBS Initiates Coverage On Evolent Health with Buy Rating, Announces Price Target of $46
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo has initiated coverage on Evolent Health (NYSE:EVH) with a Buy rating and a price target of $46.
October 16, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evolent Health has been initiated with a Buy rating by UBS, with a price target of $46. This could potentially increase investor confidence and positively impact the stock price.
Analyst ratings often influence investor sentiment and can impact stock prices. A Buy rating from a reputable institution like UBS indicates a positive outlook for the company, which could lead to increased demand for the stock and a potential rise in its price. The price target of $46 also suggests that UBS believes the stock is undervalued at its current price, which could further boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100